Evaluation of Inflammatory Markers in Philadelphia Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy

What this Trial Is About

Researchers are studying patients with Philadelphia chromosome-negative Myeloproliferative Neoplasms (MPN Ph negative) to observe inflammatory biomarkers and track their changes over the course of the disease. The study aims to find links between these biomarkers and important disease outcomes such as blood clots, bleeding events, and progression to more severe disease stages like accelerated or blast phases. This observational study is designed to improve risk assessment for patients with these blood disorders. This study is observational and does not involve experimental treatments. It gathers data on inflammatory markers and clinical events in patients diagnosed with types of MPN including polycythemia vera, essential thrombocythemia, primary myelofibrosis, and post-PV or post-ET myelofibrosis. The study collects information retrospectively and prospectively from medical records and laboratory tests over a period of up to 60 months (5 years). Participants will be monitored through routine blood counts with white cell formulas to calculate inflammatory ratios, along with tracking arterial and venous thrombotic events. The study also measures conventional and new inflammatory biomarkers, time to thrombo-hemorrhagic events, survival status, and disease progression to fibrotic, accelerated, or leukemic phases. The total observation period is planned for 60 months, and participants provide informed consent to share their data for this research.

Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.